News

FDA Upheaval Pushes Some Biotech Firms to Plan Early Trials Out of US
The FDA did not respond to a request for comment. U.S. Health Secretary Robert F. Kennedy Jr. has said that the agency's ...
Stocktwits on MSN1d
Moleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On ‘Low And Slow’ Setup
Retail chatter around Moleculin Biotech surged on Monday after the company said the European Medicines Agency had approved ...
Feds recommend pausing vaccine for mosquito-borne disease chikungunya in people over 60
The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...
Clinical Trials Arena on MSN1d
EMA approves Moleculin’s application for Phase IIb/III AML trial
The European Medicines Agency (EMA) has approved Moleculin Biotech’s clinical trial application (CTA) for a pivotal, ...
Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial
Adds nine additional countries to the Company’s ongoing pivotal Phase 3 trial; Authorization granted in all EU countries ...
BioPharma Dive2d
FDA follows EMA in limiting use of Valneva shot
Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...
News Medical on MSN27m
Research highlights extended duration of ADHD medication for Finnish children
A recent study by the University of Turku and the University of Helsinki in Finland and the Finnish Social Insurance Institution Kela reveals that the average duration of ADHD medication for children ...
BioSpace2d
FDA, EU Flag Safety Issues With Valneva’s Chikungunya Vaccine
The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...
Fierce Pharma2d
FDA, CDC call for pause of chikungunya shot rollout in older adults
On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...